Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at Edwards Lifesciences Corp as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Edwards Lifesciences Corp income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Edwards Lifesciences Corp annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Michael A. Mussallem
Former Chief Executive Officer and Chairman of the Board
Total Cash $1,206,961 Equity $399,972 Other $198,804 Total Compensation $1,805,737
Donald E. Bobo Jr.
Corporate Vice President, Strategy & Corporate Development
Total Cash $1,225,999 Equity $3,020,127 Other $45,673 Total Compensation $4,291,799
Scott B. Ullem
Corporate Vice President, Chief Financial Officer
Total Cash $1,289,424 Equity $4,599,479 Other $60,250 Total Compensation $5,949,153
Catherine M. Szyman
Corporate Vice President, Critical Care
Total Cash $1,226,148 Equity $3,075,409 Other $38,474 Total Compensation $4,340,031
Larry L. Wood
Corporate Vice President
Total Cash $1,425,852 Equity $3,909,455 Other $59,727 Total Compensation $5,395,034
Bernard J. Zovighian
Chief Executive Officer and Director
Total Cash $2,207,021 Equity $10,599,764 Other $62,235 Total Compensation $12,869,020
For its 2023 fiscal year, Edwards Lifesciences Corp, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Bernard J. Zovighian CEO Pay $13,333,852 Median Employee Pay $50,368 CEO Pay Ratio 265:1
For its 2023 fiscal year, Edwards Lifesciences Corp, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Kieran T. Gallahue Total Cash $335,056
Leslie S. Heisz Total Cash $356,422
Martha H. Marsh Total Cash $364,972
Nicholas J. Valeriani Total Cash $347,972
Paul A. LaViolette Total Cash $329,972
Ramona Sequeira Total Cash $334,972
Steven R. Loranger Total Cash $335,056

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.